Tyrosine kinase inhibitorFDA-approvedSecond-line
Dasatinib
How it works
Blocks the BCR-ABL tyrosine kinase enzyme, which is overactive in CML cells, and also inhibits other tyrosine kinases involved in cancer growth.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 70% of BCR-ABL-positive patients achieved a major cytogenetic response, with a median progression-free survival of approximately 2 years.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combining blinatumomab and dasatinib for pediatric leukemia treatment | Leukemia | observational | At a median follow-up of 13 months, all patients were alive without disease relapse. | Source → |
| Testing Blinatumomab and Tyrosine Kinase Inhibitor Therapy for Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Chronic Leukemia Relapse After Bone Marrow Transplantation | Leukemia | observational | — | Source → |
| Improving Cancer Treatment with Targeted Drug Delivery | Leukemia | lab-study | — | Source → |
| Combining Dasatinib with Chemotherapy in Leukemia Treatment | Leukemia | phase-2 | The overall MRD negativity rate was 62.5%. | Source → |
| Woman Develops Lung Injury After Taking Cancer Drug Dasatinib | Leukemia | observational | — | Source → |
| Rare Complication in Cancer Patients on Dasatinib Therapy | Leukemia | observational | — | Source → |
| Dasatinib May Harm Blood Vessels, Study Suggests | Leukemia | lab-study | — | Source → |
| Dasatinib Side Effect Study in CML Patients | Leukemia | observational | A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib. | Source → |
| Combining CBD and dasatinib may help treat lung cancer | Lung Cancer | lab-study | The combination of CBD and low-dose dasatinib exhibited a ZIP of > 10, indicating significant synergistic apoptosis. | Source → |
| Dasatinib and Low-Intensity Chemotherapy for a Rare Blood Cancer | Leukemia | phase-2 | The estimated 3-year disease-free survival was 52.4% and overall survival was 73.2%. | Source → |
| New Treatment Approach for Adult Leukemia Shows Promise | Leukemia | phase-3 | Disease-free survival, overall survival, and event-free survival are 75.8%, 80.7%, and 74.6%, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.